LONDON--(BUSINESS WIRE)--Citi, acting through Citibank N.A., has been appointed by Teva Pharmaceutical Industries Ltd. (“Teva”) as successor depositary bank for its American Depositary Receipt (“ADR”) programme. Teva’s ADRs trade on the New York Stock Exchange (“NYSE”) under the symbol “TEVA.” Each ADR represents one ordinary share of Teva.”
“We are proud to have been selected by Teva as successor ADR depositary bank for its NYSE listed ADR programme,” said Dirk Jones, Global Head of Issuer Services, at Citi. “With Citi’s global presence and investor relations expertise, we are confident our platform will help to facilitate the continued success of the Teva ADR programme and provide its investors with the highest quality ADR services.”
For more information on Citi’s Depositary Receipt Services, visit www.citi.com/dr.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and
TASE: TEVA) is a global leader in generic medicines, with innovative
treatments in select areas, including CNS, pain and respiratory. We
deliver high-quality generic products and medicines in nearly every
therapeutic area to address unmet patient needs. We have an established
presence in generics, specialty, OTC and API, building on more than a
century-old legacy, with a fully integrated R&D function, strong
operational base and global infrastructure and scale. We strive to act
in a socially and environmentally responsible way. Headquartered in
Israel, with production and research facilities around the globe, we
employ 45,000 professionals, committed to improving the lives of
millions of patients. Learn more at www.tevapharm.com.
About Citi
Citi, the leading global bank, has approximately
200 million customer accounts and does business in more than 160
countries and jurisdictions. Citi provides consumers, corporations,
governments and institutions with a broad range of financial products
and services, including consumer banking and credit, corporate and
investment banking, securities brokerage, transaction services, and
wealth management.
Additional information may be found at www.citigroup.com | Twitter: @Citi | YouTube: www.youtube.com/citi | Blog: http://blog.citigroup.com | Facebook: www.facebook.com/citi | LinkedIn: www.linkedin.com/company/citi
